Abstract
Background
Serum Golgi membrane protein 1 (GOLM1) is a novel biomarker for hepatocellular carcinoma (HCC). However, few studies have investigated the relationship between GOLM1 protein expression and clinicopathologic features in HCC patients. The aim of this study was to investigate the expression of GOLM1 in human HCC and its correlation with clinicopathologic parameters.
Methods
Clinicopathologic data were obtained through a detailed retrospective review of the medical records of 193 patients with HCC who had undergone surgical resection between 1990 and 2006 at the Taipei Veterans General Hospital. Another 120 HCC tissue samples provided by the Taiwan Liver Cancer Network were used as validation cohort. Immunohistochemical staining was used to determine the expression of GOLM1 in archived formalin-fixed, paraffin-embedded tissue specimens.
Results
GOLM1 expression was significantly higher in resected HCC tumor tissues than in corresponding normal liver tissues (p < 0.01). After a median follow-up of 51 months, multivariate analysis showed that portal vein invasion (hazard ratio [HR], 1.515; 95 % confidence interval [95 % CI], 1.008–2.277; p = 0.046) and high GOLM1 protein expression (HR, 1.696; 95 % CI, 1.160–2.479; p = 0.006) were independent prognostic factors for poor overall survival. High GOLM1 protein expression still significantly correlates with worse overall survival as well as disease-free survival in the validation cohort (p < 0.001 and p = 0.002).
Conclusions
Overexpression of GOLM1 is associated with poor prognosis in human HCC.
Similar content being viewed by others
Reference
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763.
Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000;6:320–325.
Min YW, Gwak GY, Lee MW, Choi MS, Lee JH, Koh KC, et al. Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. World J Gastroenterol. 2012;18:2654–2660.
Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.
Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–66.
Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis. 2006;38:854–859.
Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yüksel O, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2011;83:83–88.
Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59:1687–1693.
Li X, Wu K, Fan D. Serum Golgi Phosphoprotein two level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology. 2009;50:325.
Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000;249:53–65.
Zhou Y, Li L, Hu L, Peng T. Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol Biol Rep. 2011;38:1457–1462.
Hu L, Li L, Xie H, Gu Y, Peng T. The Golgi localization of GOLPH2 (GP73/GOLM1) is determined by the transmembrane and cytoplasmic sequences. PloS One. 2011;6:e28207.
Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938–947.
Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291–299.
Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, et al. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J Gastroenterol. 2013;48:101–108.
Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49:1602–1609.
Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35:1431–1440.
Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 2011;26:1207–1212.
Ando E, Kuromatsu R, Tanaka M, Takada A, Fukushima N, Sumie S, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol. 2006;40:942–948.
Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol. 2012;19:3687–3696.
Acknowledgment
This research was supported by grants from Taipei Veterans General Hospital (V102E2-007), Yen Tjing Ling Medical Foundation and Taiwan Clinical Oncology Research Foundation to M.-H. Chen and National Science Council (NSC100-2627-B-010-005), National Health Research Institutes (NHRI-EX101-10029BI), Taipei Veterans General Hospital (V102E2-006 and VGHUST101-G5-1-2), and Ministry of Education Aim for the Top University Plan (National Yang Ming University) to C. Y. Huang. We would like to thank Taiwan Liver Cancer Network (TLCN) for providing the HCC tissue samples and related clinical data (all are anonymous) for our research work. This network currently includes five major medical centers (National Taiwan University Hospital, Chang-Gung Memorial Hospital-Linko, Veteran General Hospital-Taichung, Chang-Gung Memorial Hospital -Kaohsiung, and Veteran General Hospital -Kaohsiung). TLCN is supported by grants from National Science Council since 2005 till now (NSC 100-2325 -B-182 -006) and National Health Research Institutes, Taiwan.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Ming-Huang Chen and Yi-Hua Jan contributed equally to this work.
Rights and permissions
About this article
Cite this article
Chen, MH., Jan, YH., Chang, P.MH. et al. Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma. Ann Surg Oncol 20 (Suppl 3), 616–624 (2013). https://doi.org/10.1245/s10434-013-3101-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-013-3101-8